ClinicalTrials.gg
CompletedNCT01384734Updated Nov 14, 2018Results posted

HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections

A Phase 2 interventional study of BMS-663068 400 mg and BMS-663068 800 mg in Infection, Human Immunodeficiency Virus, sponsored by ViiV Healthcare. Completed at 56 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-11-14.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
254
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to assess the safety, efficacy, tolerability and pharmacokinetics of four doses of BMS-663068 with Raltegravir (RAL) + Tenofovir Disoproxil Fumarate (TDF). At least 1 dose of BMS-663068 can be identified which is safe, well tolerated, and efficacious when combined with RAL + TDF for treatment-experienced HIV-1 infected subjects. PHENOSENSE® is a registered trademark of Monogram Biosciences.

Read the detailed description

Masking: Double-blind for BMS-6630368 treatment groups until the Week 24 Primary Endpoint analysis, then open label. The reference groups is all open-label.

Arms: 5 (4 BMS-663068 treatment groups and 1 reference group)

Intervention Model: Parallel (with unblinding after the Week 24 primary endpoint analysis)

02

Conditions studied

  • Infection, Human Immunodeficiency Virus
03

In context

Infections

2,096 studies on the registry are indexed under Infections; 364 are open to participants now.

This study's enrollment of 254 is above the median of 113 across 1,305 interventional studies indexed under Infections.

Browse Infections studies →

Lead sponsor

ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.

Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Plasma -1 RNA ≥ 1000 copies/ml at Screening
  • Treatment experience with antiretroviral therapies (excluding integrase inhibitors)
  • Screening PHENOSENSE Entry indicating BMS-626529 inhibitory concentration (IC)50 \< 0.1 μM
  • Cluster of differentiation (CD)4+ T-cell count > 50 cells/mm3

Exclusion criteria

Exclusion Criteria:

  • History (or evidence at Screening) of genotypic resistance to any component of the study regimen [ Tenofovir Disoproxil Fumarate (TDF), Atazanavir (ATV), Raltegravir (RAL)]
  • Certain laboratory and (ECG) values
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
254 participants (actual)

Study arms

  • Experimental
    Arm A: BMS-663068 (400mg) + Raltegravir + Tenofovir

    Treatment Group 1

    Drug: BMS-663068 400 mg · Drug: Raltegravir 400 mg · Drug: Tenofovir 300 mg

  • Experimental
    Arm B: BMS-663068 (800 mg) + Raltegravir + Tenofovir

    Treatment Group 2

    Drug: BMS-663068 800 mg · Drug: Raltegravir 400 mg · Drug: Tenofovir 300 mg

  • Experimental
    Arm C: BMS-663068 (600 mg) + Raltegravir + Tenofovir

    Treatment Group 3

    Drug: BMS-663068 600 mg · Drug: Raltegravir 400 mg · Drug: Tenofovir 300 mg

  • Experimental
    Arm D: BMS-663068 (1200 mg) + Raltegravir + Tenofovir

    Treatment Group 4

    Drug: BMS-663068 1200 mg · Drug: Raltegravir 400 mg · Drug: Tenofovir 300 mg

  • Active comparator
    Arm E: Atazanavir + Ritonavir + Raltegravir + Tenofovir

    Treatment Group 1 (reference arm)

    Drug: Raltegravir 400 mg · Drug: Tenofovir 300 mg · Drug: Ritonavir 100 mg · Drug: Atazanavir 300 mg

Interventions

  • Tablets, Oral, 400 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose

  • Tablets, Oral, 800 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose

  • Tablets, Oral, 600 mg, once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose

  • Tablets, Oral, 1200 mg, once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose

  • Tablets, Oral, 400 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose

  • Tablets, Oral, 300 mg, Once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose

  • Tablets, Oral, 100 mg, Once daily, 96 weeks

  • Capsules, Oral, 300 mg, Once daily, 96 weeks

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Plasma HIV-1 Ribonucleic Acid (RNA) < 50 Copies Per Milliliter (c/mL) at Week 24

    Percentage of participants with plasma HIV 1 RNA \< 50 c/mL at Week 24 using the Food and Drug Administration (FDA) snapshot algorithm was assessed to evaluate the antiviral activity. Treatment comparisons were not performed as this was an estimation study. Response rates were tabulated by treatment arm with exact Clopper-Pearson binomial 95 percentage confidence intervals (CI). Virologic success or failure was determined by the last available HIV-1 RNA assessment while the participant was on-treatment within the snapshot window of the visit of interest. Intent-To-Treat-Exposed (ITT-E) Population includes all randomized participants who received at least one dose of study treatment.

    Time frame: Week 24

  2. Number of Participants With Serious Adverse Events (SAE) and Discontinuation Due to AEs up to Week 24

    Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment or suspected transmission of an infectious agent via the study drug were categorized as SAE. AEs leading to discontinuation of study therapy were also reported as safety assessment. Safety population included all participants who received at least one dose of study treatment. Summaries of SAEs and AEs leading to discontinuation or withdrawal through Week 24 included AEs with onset on or after the start of study treatment (i.e. study date of first study treatment intake) up to and including the end of the Week 24 visit snapshot window.

    Time frame: Up to Week 24

Secondary outcomes

  1. Change From Monotherapy Baseline in log10 HIV RNA of the Monotherapy Period

    Change from monotherapy Baseline in log10 HIV RNA to assess the antiviral activity of temsavir following administration of selected doses of FTR administered orally to HIV-1-infected participants for 7 days. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment. Change from Baseline was calculated as value at indicated time point minus Baseline value. ITT-E Monotherapy Population comprised of participants that were randomized and participated in the monotherapy sub-study and received at least one dose of FTR Monotherapy. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).

    Time frame: Baseline and up to Day 8 of the monotherapy period

  2. Maximum Decrease From Monotherapy Baseline in log10 Plasma HIV-1 RNA

    Maximum decrease from monotherapy Baseline in log10 plasma HIV-1 RNA during monotherapy to assess the antiviral activity of temsavir following administration of selected doses of FTR administered orally to HIV-1-infected participants for 7 days. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment. Change from Baseline was calculated as value at indicated time point minus Baseline value. The data for monotherapy nadir has been presented where nadir represents the maximum decrease from Baseline.

    Time frame: Baseline and up to Day 8 of the monotherapy period

  3. Percentage of Participants With Plasma HIV-1 RNA < 50 c/mL at Day 8 of the Monotherapy Period

    Percentage of participants with plasma HIV 1 RNA \< 50 c/mL at Baseline of combination therapy was assessed to evaluate the antiviral activity of four doses of FTR. Baseline of combination therapy was the Day 1 of the combination therapy. Virologic success or failure was determined using the non-missing viral load value at Baseline of combination therapy. The assessment closest to the window target Study Day was used for the analysis. Only those participants with data available at the specified time points were analyzed.

    Time frame: Up to Day 8 of the monotherapy period

  4. Number of Participants With SAE and Discontinuation Due to AEs During Monotherapy Period

    Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment or suspected transmission of an infectious agent via the study drug were categorized as SAE. AEs leading to discontinuation of study therapy were also reported as safety assessment.

    Time frame: Up to Day 8 of the monotherapy period

  5. Change From Monotherapy Baseline in Cluster of Differentiation (CD)4+ and CD8+ T-cell Counts During Monotherapy

    Blood was collected and CD4+ and CD8+ cell count assessment was done by flow cytometery and was carried out at Baseline (Day 1) to evaluate the immunological activity of multiple doses of FTR. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment and the values are absolute values. Change from Baseline was calculated as value at indicated time point minus Baseline value. Only those participants with data available at the specified time points were analyzed.

    Time frame: Baseline and Day 8

  6. Change From Monotherapy Baseline in CD4+ and CD8+ T-cell Proportion During Monotherapy

    Blood was collected and CD4+ and CD8+ proportion assessment was done by flow cytometery and was carried out at Baseline (Day 1) to evaluate the immunological activity of multiple doses of FTR. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment and the values are absolute values. Change from Baseline was calculated as value at indicated time point minus Baseline value. Only those participants with data available at the specified time points were analyzed.

    Time frame: Baseline and Day 8

  7. Percentage of Participants With Plasma HIV-1 RNA < 50 c/mL at Primary Study

    Percentage of participants with plasma HIV 1 RNA \< 50 c/mL at Weeks 48 and 96 using the FDA snapshot algorithm was assessed to evaluate the antiviral activity. Treatment comparisons were not performed as this was an estimation study. Response rates were tabulated by treatment arm with exact Clopper-Pearson binomial 95 percentage CI. Virologic success or failure was determined by the last available HIV-1 RNA assessment while the participant was on-treatment within the snapshot window of the visit of interest.

    Time frame: Weeks 48 and 96

  8. Number of Participants With SAE and Discontinuation Due to AEs During Primary Study

    Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment or suspected transmission of an infectious agent via the study drug were categorized as SAE. AEs leading to discontinuation of study therapy were also reported as safety assessment. Safety Population comprised of participants who received at least one dose of study treatment. Summaries of SAEs and AEs leading to discontinuation or withdrawal through Week X (where X = 48 or 96) included AEs with onset on or after the start of study treatment (i.e. study date of first study treatment intake) up to and including the end of the Week 48 and 96 visit snapshot window.

    Time frame: Weeks 48 and 96

  9. Change From Baseline in CD4+ T-cell Count

    Blood was collected and CD4+ cell count assessment by flow cytometery was carried out at Baseline (Day 1), Weeks 24, 48 and 96 to evaluate the immunological activity of multiple doses of BMS-663068/GSK3684934. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment and those values are absolute values. Change from Baseline was calculated as value at indicated time point minus Baseline value. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).

    Time frame: Baseline and Weeks 24, 48 and 96

  10. Number of Participants With Newly-emergent Genotypic Substitutions at Week 24

    Participants who administered antiretroviral (ARV) with virologic failure (VF) were assessed. Genotypic substitution included assessment of Reverse Transcriptase (RT) substitution, Protease Inhibitor (PI) substitution and Integrase RAL substitution as per International Acquired Immune Deficiency Syndrome (AIDS) Society-USA (IAS-USA) list. ITT-E Resistance Tested through Week 24 population included participants who met the criteria for Resistance testing, and the confirmatory value or value at discontinuation occurred at or before the end of the Week 24 Snapshot analysis window. The criteria for resistance tested was participant who had virologic failure or met the following criteria a) Participants who achieved viral suppression (plasma HIV-1 RNA \< 50 c/mL) and have confirmed plasma HIV-1 RNA \>= 400 c/mL at any time during the study. b) Participants who were discontinued before achieving viral suppression (plasma HIV-1 RNA \< 50 c/mL) after Week 8 with last plasma HIV-1 RNA \>=400 c/mL.

    Time frame: Up to Week 24

  11. Number of Participants With Newly-emergent Genotypic Substitutions at Week 48

    Participants who administered ARV with VF were assessed. Genotypic substitution included assessment of RT substitution, PI substitution and Integrase RAL substitution as per IAS-USA list. ITT-E Resistance Tested through Week 48 population included participants who met the criteria for Resistance testing, and the confirmatory value or value at discontinuation occurred at or before the end of the Week 48 Snapshot analysis window. The criteria for resistance tested was participant who had virologic failure or the following criteria a) Participants who achieved viral suppression (plasma HIV-1 RNA \< 50 c/mL) and have confirmed plasma HIV-1 RNA \>= 400 c/mL at any time during the study. b) Participants who were discontinued before achieving viral suppression (plasma HIV-1 RNA \< 50 c/mL) after Week 8 with last plasma HIV-1 RNA \>=400 c/mL.

    Time frame: Up to Week 48

  12. Number of Participants With Newly-emergent Genotypic Substitutions at Week 96

    Participants who administered ARV with VF were assessed. Genotypic substitution included assessment of RT substitution, PI substitution and Integrase RAL substitution as per IAS-USA list. ITT-E Resistance Tested through Week 96 population included participants who met the criteria for Resistance testing, and the confirmatory value or value at discontinuation occurred at or before the end of the Week 96 Snapshot analysis window. The criteria for resistance tested was participants with virologic failure or the following criteria a) Participants who achieved viral suppression (plasma HIV-1 RNA \< 50 c/mL) and have confirmed plasma HIV-1 RNA \>= 400 c/mL at any time during the study. b) Participants who were discontinued before achieving viral suppression (plasma HIV-1 RNA \< 50 c/mL) after Week 8 with last plasma HIV-1 RNA \>=400 c/mL.

    Time frame: Up to Week 96

  13. Maximum Change From Baseline in Inhibitory Concentration at 50% (IC50) Fold Change Among Participants With VF at Week 24

    Virologic failure is defined clinically as confirmed plasma HIV-1 RNA \>= 50 copies/mL at Week 24 or later or virologic rebound defined as confirmed HIV-1 RNA \>=50 copies/mL at any time after prior confirmed suppression to \<50 copies/mL OR confirmed \>1 log10 copies/mL increase in HIV-1 RNA at any time above nadir level where nadir was \>= 50 copies/mL . The phenotypic resistance to a drug is defined as a fold change (i.e, ratio of the IC50 of the clinical isolate to the IC50 of the reference strain) greater than the cut-off for reduced susceptibility. Maximum change from Baseline in Temsavir IC50 fold change based on all on-treatment values has been presented. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment and those values are absolute values. Change from Baseline was calculated as value at indicated time point minus Baseline value. Only those participants available at the specified time points were analyzed.

    Time frame: Baseline and up to Week 24

  14. Change From Baseline in IC50 Fold Change Among Participants With VF at Week 48

    Virologic failure is defined clinically as confirmed plasma HIV-1 RNA \>= 50 copies/mL at Week 24 or later or later or virologic rebound defined as confirmed HIV-1 RNA \>=50 copies/mL at any time after prior confirmed suppression to \<50 copies/mL OR confirmed \>1 log10 copies/mL increase in HIV-1 RNA at any time above nadir level where nadir was \>= 50 copies/mL. The phenotypic resistance to a drug is defined as a fold change (i.e, ratio of the IC50 of the clinical isolate to the IC50 of the reference strain) greater than the cut-off for reduced susceptibility. Maximum change from Baseline in Temsavir IC50 fold change based on all on-treatment values has been presented. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment and those values are absolute values. Change from Baseline was calculated as value at indicated time point minus Baseline value. Only those participants available at the specified time points were analyzed.

    Time frame: Baseline and up to Week 48

  15. Change From Baseline in IC50 Fold Change Among Participants With VF at Week 96

    Virologic failure is defined clinically as confirmed plasma HIV-1 RNA \>= 50 copies/mL at Week 24 or later or virologic rebound defined as confirmed HIV-1 RNA \>=50 copies/mL at any time after prior confirmed suppression to \<50 copies/mL OR confirmed \>1 log10 copies/mL increase in HIV-1 RNA at any time above nadir level where nadir was \>= 50 copies/mL. The phenotypic resistance to a drug is defined as a fold change (i.e, ratio of the IC50 of the clinical isolate to the IC50 of the reference strain) greater than the cut-off for reduced susceptibility. Maximum change from Baseline in Temsavir IC50 fold change based on all on-treatment values has been presented. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment and those values are absolute values. Change from Baseline was calculated as value at indicated time point minus Baseline value. Only those participants available at the specified time points were analyzed.

    Time frame: Baseline and up to Week 96

07

Results

Posted Nov 14, 2018

Participant flow

Participants with Human Immunodeficiency Virus (HIV-1) were randomized in ratio of 1:1:1:1:1 to 5 treatment arms of the study. Four groups with distinct dose of Fostemsavir (FTR, also referred BMS-663068) with Raltegravir (RAL) Tenofovir Disoproxil Fumarate (TDF). There was a reference group with ritonavir (r) boosted atazanavir (ATV), RAL and TDF.

Participant flow — Overall Study
MilestoneFTR 400 mg BID/RAL/TDFFTR 800 mg BID/RAL/TDFFTR 600 mg QD/RAL/TDFFTR 1200 mg QD/RAL/TDFATV/r/RAL/TDF
Started5049515051
Completed3325282222
Not completed1724232829
Withdrew: Adverse event03027
Withdrew: Death10100
Withdrew: Continuation criteria not met00110
Withdrew: Lack of efficacy37442
Withdrew: Lost to follow-up53385
Withdrew: Non-compliance with study drug12602
Withdrew: Pregnancy01001
Withdrew: Sponsor terminated00001
Withdrew: Withdrawal by subject55679
Withdrew: Investigator relocating02031
Withdrew: Unable to come back for visit10110
Withdrew: Prison00100
Withdrew: As per exclusion criteria01000
Withdrew: Missed end of treatment visit00010
Withdrew: Adhesion problem00010
Withdrew: Early termination00001
Withdrew: Physician decision10000

Outcome measures

PrimaryPercentage of Participants With Plasma HIV-1 Ribonucleic Acid (RNA) < 50 Copies Per Milliliter (c/mL) at Week 24

Percentage of participants with plasma HIV 1 RNA \< 50 c/mL at Week 24 using the Food and Drug Administration (FDA) snapshot algorithm was assessed to evaluate the antiviral activity. Treatment comparisons were not performed as this was an estimation study. Response rates were tabulated by treatment arm with exact Clopper-Pearson binomial 95 percentage confidence intervals (CI). Virologic success or failure was determined by the last available HIV-1 RNA assessment while the participant was on-treatment within the snapshot window of the visit of interest. Intent-To-Treat-Exposed (ITT-E) Population includes all randomized participants who received at least one dose of study treatment.

Time frame:
Week 24
Reported as:
Number · Percentage of Participants
Percentage of Participants With Plasma HIV-1 Ribonucleic Acid (RNA) < 50 Copies Per Milliliter (c/mL) at Week 24
Percentage of ParticipantsFTR 400 mg BID/RAL/TDFFTR 800 mg BID/RAL/TDFFTR 600 mg QD/RAL/TDFFTR 1200 mg QD/RAL/TDFATV/r/RAL/TDF
Percentage of Participants With Plasma HIV-1 Ribonucleic Acid (RNA) < 50 Copies Per Milliliter (c/mL) at Week 2480 (66.3 to 90.0)69 (54.6 to 81.7)76 (62.5 to 87.2)72 (57.5 to 83.8)75 (60.4 to 85.7)
PrimaryNumber of Participants With Serious Adverse Events (SAE) and Discontinuation Due to AEs up to Week 24

Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment or suspected transmission of an infectious agent via the study drug were categorized as SAE. AEs leading to discontinuation of study therapy were also reported as safety assessment. Safety population included all participants who received at least one dose of study treatment. Summaries of SAEs and AEs leading to discontinuation or withdrawal through Week 24 included AEs with onset on or after the start of study treatment (i.e. study date of first study treatment intake) up to and including the end of the Week 24 visit snapshot window.

Time frame:
Up to Week 24
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events (SAE) and Discontinuation Due to AEs up to Week 24
ParticipantsFTR 400 mg BID/RAL/TDFFTR 800 mg BID/RAL/TDFFTR 600 mg QD/RAL/TDFFTR 1200 mg QD/RAL/TDFATV/r/RAL/TDF
SAE34425
AEs leading to discontinuation12012
SecondaryChange From Monotherapy Baseline in log10 HIV RNA of the Monotherapy Period

Change from monotherapy Baseline in log10 HIV RNA to assess the antiviral activity of temsavir following administration of selected doses of FTR administered orally to HIV-1-infected participants for 7 days. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment. Change from Baseline was calculated as value at indicated time point minus Baseline value. ITT-E Monotherapy Population comprised of participants that were randomized and participated in the monotherapy sub-study and received at least one dose of FTR Monotherapy. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).

Time frame:
Baseline and up to Day 8 of the monotherapy period
Reported as:
Mean · log10 c/mL
Change From Monotherapy Baseline in log10 HIV RNA of the Monotherapy Period
log10 c/mLFTR 400 mg BID/RAL/TDFFTR 800 mg BID/RAL/TDFFTR 600 mg QD/RAL/TDFFTR 1200 mg QD/RAL/TDF
Day 2, n=7, 5, 10, 90.220 ± 0.16300.149 ± 0.18200.126 ± 0.18110.126 ± 0.4216
Day 5, n=7, 4, 10, 10-0.340 ± 0.3185-0.811 ± 0.3455-0.593 ± 0.2429-0.767 ± 0.6388
Day 6, n=7, 5, 10, 10-0.530 ± 0.3170-1.082 ± 0.3388-0.822 ± 0.3076-1.053 ± 0.7491
Day 7, n=6, 5, 10, 10-0.556 ± 0.4264-1.443 ± 0.4484-1.086 ± 0.4216-1.198 ± 0.6863
Day 8, n=6, 4, 9, 9-0.691 ± 0.5380-1.372 ± 0.3208-1.218 ± 0.3902-1.470 ± 0.6570
SecondaryMaximum Decrease From Monotherapy Baseline in log10 Plasma HIV-1 RNA

Maximum decrease from monotherapy Baseline in log10 plasma HIV-1 RNA during monotherapy to assess the antiviral activity of temsavir following administration of selected doses of FTR administered orally to HIV-1-infected participants for 7 days. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment. Change from Baseline was calculated as value at indicated time point minus Baseline value. The data for monotherapy nadir has been presented where nadir represents the maximum decrease from Baseline.

Time frame:
Baseline and up to Day 8 of the monotherapy period
Reported as:
Mean · log10 c/mL
Maximum Decrease From Monotherapy Baseline in log10 Plasma HIV-1 RNA
log10 c/mLFTR 400 mg BID/RAL/TDFFTR 800 mg BID/RAL/TDFFTR 600 mg QD/RAL/TDFFTR 1200 mg QD/RAL/TDF
Maximum Decrease From Monotherapy Baseline in log10 Plasma HIV-1 RNA-0.770 ± 0.4487-1.524 ± 0.3898-1.250 ± 0.3818-1.399 ± 0.6688
SecondaryPercentage of Participants With Plasma HIV-1 RNA < 50 c/mL at Day 8 of the Monotherapy Period

Percentage of participants with plasma HIV 1 RNA \< 50 c/mL at Baseline of combination therapy was assessed to evaluate the antiviral activity of four doses of FTR. Baseline of combination therapy was the Day 1 of the combination therapy. Virologic success or failure was determined using the non-missing viral load value at Baseline of combination therapy. The assessment closest to the window target Study Day was used for the analysis. Only those participants with data available at the specified time points were analyzed.

Time frame:
Up to Day 8 of the monotherapy period
Reported as:
Number · Percentage of Participants
Percentage of Participants With Plasma HIV-1 RNA < 50 c/mL at Day 8 of the Monotherapy Period
Percentage of ParticipantsFTR 400 mg BID/RAL/TDFFTR 800 mg BID/RAL/TDFFTR 600 mg QD/RAL/TDFFTR 1200 mg QD/RAL/TDF
Percentage of Participants With Plasma HIV-1 RNA < 50 c/mL at Day 8 of the Monotherapy Period0 (0.0 to 45.9)0 (0.0 to 60.2)0 (0.0 to 33.6)11 (0.3 to 48.2)
SecondaryNumber of Participants With SAE and Discontinuation Due to AEs During Monotherapy Period

Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment or suspected transmission of an infectious agent via the study drug were categorized as SAE. AEs leading to discontinuation of study therapy were also reported as safety assessment.

Time frame:
Up to Day 8 of the monotherapy period
Reported as:
Count of participants · Participants
Number of Participants With SAE and Discontinuation Due to AEs During Monotherapy Period
ParticipantsFTR 400 mg BID/RAL/TDFFTR 800 mg BID/RAL/TDFFTR 600 mg QD/RAL/TDFFTR 1200 mg QD/RAL/TDF
SAE0000
AEs leading to discontinuation0000
SecondaryChange From Monotherapy Baseline in Cluster of Differentiation (CD)4+ and CD8+ T-cell Counts During Monotherapy

Blood was collected and CD4+ and CD8+ cell count assessment was done by flow cytometery and was carried out at Baseline (Day 1) to evaluate the immunological activity of multiple doses of FTR. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment and the values are absolute values. Change from Baseline was calculated as value at indicated time point minus Baseline value. Only those participants with data available at the specified time points were analyzed.

Time frame:
Baseline and Day 8
Reported as:
Mean · cells per cubic millimeter
Change From Monotherapy Baseline in Cluster of Differentiation (CD)4+ and CD8+ T-cell Counts During Monotherapy
cells per cubic millimeterFTR 400 mg BID/RAL/TDFFTR 800 mg BID/RAL/TDFFTR 600 mg QD/RAL/TDFFTR 1200 mg QD/RAL/TDF
CD4+58.4 ± 81.60134.8 ± 25.7071.8 ± 117.6863.4 ± 100.86
CD8+134.2 ± 180.64216.3 ± 215.57188.0 ± 363.5867.6 ± 236.55
SecondaryChange From Monotherapy Baseline in CD4+ and CD8+ T-cell Proportion During Monotherapy

Blood was collected and CD4+ and CD8+ proportion assessment was done by flow cytometery and was carried out at Baseline (Day 1) to evaluate the immunological activity of multiple doses of FTR. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment and the values are absolute values. Change from Baseline was calculated as value at indicated time point minus Baseline value. Only those participants with data available at the specified time points were analyzed.

Time frame:
Baseline and Day 8
Reported as:
Mean · cells per cubic millimeter
Change From Monotherapy Baseline in CD4+ and CD8+ T-cell Proportion During Monotherapy
cells per cubic millimeterFTR 400 mg BID/RAL/TDFFTR 800 mg BID/RAL/TDFFTR 600 mg QD/RAL/TDFFTR 1200 mg QD/RAL/TDF
CD4+-0.005 ± 0.00840.023 ± 0.02990.008 ± 0.03350.014 ± 0.0320
CD8+-0.003 ± 0.0273-0.040 ± 0.0245-0.009 ± 0.0465-0.021 ± 0.0364
SecondaryPercentage of Participants With Plasma HIV-1 RNA < 50 c/mL at Primary Study

Percentage of participants with plasma HIV 1 RNA \< 50 c/mL at Weeks 48 and 96 using the FDA snapshot algorithm was assessed to evaluate the antiviral activity. Treatment comparisons were not performed as this was an estimation study. Response rates were tabulated by treatment arm with exact Clopper-Pearson binomial 95 percentage CI. Virologic success or failure was determined by the last available HIV-1 RNA assessment while the participant was on-treatment within the snapshot window of the visit of interest.

Time frame:
Weeks 48 and 96
Reported as:
Number · Percentage of Participants
Percentage of Participants With Plasma HIV-1 RNA < 50 c/mL at Primary Study
Percentage of ParticipantsFTR 400 mg BID/RAL/TDFFTR 800 mg BID/RAL/TDFFTR 600 mg QD/RAL/TDFFTR 1200 mg QD/RAL/TDFATV/r/RAL/TDF
Week 4882 (68.6 to 91.4)61 (46.2 to 74.8)69 (54.1 to 80.9)68 (53.3 to 80.5)71 (56.2 to 82.5)
Week 9678 (64.0 to 88.5)49 (34.4 to 63.7)63 (48.1 to 75.9)58 (43.2 to 71.8)57 (42.2 to 70.7)
SecondaryNumber of Participants With SAE and Discontinuation Due to AEs During Primary Study

Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment or suspected transmission of an infectious agent via the study drug were categorized as SAE. AEs leading to discontinuation of study therapy were also reported as safety assessment. Safety Population comprised of participants who received at least one dose of study treatment. Summaries of SAEs and AEs leading to discontinuation or withdrawal through Week X (where X = 48 or 96) included AEs with onset on or after the start of study treatment (i.e. study date of first study treatment intake) up to and including the end of the Week 48 and 96 visit snapshot window.

Time frame:
Weeks 48 and 96
Reported as:
Count of participants · Participants
Number of Participants With SAE and Discontinuation Due to AEs During Primary Study
ParticipantsFTR 400 mg BID/RAL/TDFFTR 800 mg BID/RAL/TDFFTR 600 mg QD/RAL/TDFFTR 1200 mg QD/RAL/TDFATV/r/RAL/TDF
SAE, Week 4835425
SAE, Week 9657647
AEs leading to discontinuation, Week 4812013
AEs leading to discontinuation, Week 9612025
SecondaryChange From Baseline in CD4+ T-cell Count

Blood was collected and CD4+ cell count assessment by flow cytometery was carried out at Baseline (Day 1), Weeks 24, 48 and 96 to evaluate the immunological activity of multiple doses of BMS-663068/GSK3684934. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment and those values are absolute values. Change from Baseline was calculated as value at indicated time point minus Baseline value. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).

Time frame:
Baseline and Weeks 24, 48 and 96
Reported as:
Mean · Cells per cubic millimeter
Change From Baseline in CD4+ T-cell Count
Cells per cubic millimeterFTR 400 mg BID/RAL/TDFFTR 800 mg BID/RAL/TDFFTR 600 mg QD/RAL/TDFFTR 1200 mg QD/RAL/TDFATV/r/RAL/TDF
Week 24, n=41, 38, 48, 42, 40134.3 ± 84.63111.0 ± 123.75109.5 ± 87.20124.5 ± 111.04119.4 ± 142.85
Week 48, n=43, 34, 43, 41, 41199.1 ± 124.24158.7 ± 118.70140.5 ± 97.16155.4 ± 107.06178.7 ± 133.90
Week 96, n=42, 28, 35, 28, 31264.6 ± 147.83210.8 ± 158.03175.7 ± 98.28211.7 ± 151.03250.1 ± 217.54
SecondaryNumber of Participants With Newly-emergent Genotypic Substitutions at Week 24

Participants who administered antiretroviral (ARV) with virologic failure (VF) were assessed. Genotypic substitution included assessment of Reverse Transcriptase (RT) substitution, Protease Inhibitor (PI) substitution and Integrase RAL substitution as per International Acquired Immune Deficiency Syndrome (AIDS) Society-USA (IAS-USA) list. ITT-E Resistance Tested through Week 24 population included participants who met the criteria for Resistance testing, and the confirmatory value or value at discontinuation occurred at or before the end of the Week 24 Snapshot analysis window. The criteria for resistance tested was participant who had virologic failure or met the following criteria a) Participants who achieved viral suppression (plasma HIV-1 RNA \< 50 c/mL) and have confirmed plasma HIV-1 RNA \>= 400 c/mL at any time during the study. b) Participants who were discontinued before achieving viral suppression (plasma HIV-1 RNA \< 50 c/mL) after Week 8 with last plasma HIV-1 RNA \>=400 c/mL.

Time frame:
Up to Week 24
Reported as:
Count of participants · Participants
Number of Participants With Newly-emergent Genotypic Substitutions at Week 24
ParticipantsFTR 400 mg BID/RAL/TDFFTR 800 mg BID/RAL/TDFFTR 600 mg QD/RAL/TDFFTR 1200 mg QD/RAL/TDFATV/r/RAL/TDF
PI substitution00000
RT substitution00010
Integrase substitution00110
SecondaryNumber of Participants With Newly-emergent Genotypic Substitutions at Week 48

Participants who administered ARV with VF were assessed. Genotypic substitution included assessment of RT substitution, PI substitution and Integrase RAL substitution as per IAS-USA list. ITT-E Resistance Tested through Week 48 population included participants who met the criteria for Resistance testing, and the confirmatory value or value at discontinuation occurred at or before the end of the Week 48 Snapshot analysis window. The criteria for resistance tested was participant who had virologic failure or the following criteria a) Participants who achieved viral suppression (plasma HIV-1 RNA \< 50 c/mL) and have confirmed plasma HIV-1 RNA \>= 400 c/mL at any time during the study. b) Participants who were discontinued before achieving viral suppression (plasma HIV-1 RNA \< 50 c/mL) after Week 8 with last plasma HIV-1 RNA \>=400 c/mL.

Time frame:
Up to Week 48
Reported as:
Count of participants · Participants
Number of Participants With Newly-emergent Genotypic Substitutions at Week 48
ParticipantsFTR 400 mg BID/RAL/TDFFTR 800 mg BID/RAL/TDFFTR 600 mg QD/RAL/TDFFTR 1200 mg QD/RAL/TDFATV/r/RAL/TDF
PI substitution10010
RT substitution00020
Integrase substitution11120
SecondaryNumber of Participants With Newly-emergent Genotypic Substitutions at Week 96

Participants who administered ARV with VF were assessed. Genotypic substitution included assessment of RT substitution, PI substitution and Integrase RAL substitution as per IAS-USA list. ITT-E Resistance Tested through Week 96 population included participants who met the criteria for Resistance testing, and the confirmatory value or value at discontinuation occurred at or before the end of the Week 96 Snapshot analysis window. The criteria for resistance tested was participants with virologic failure or the following criteria a) Participants who achieved viral suppression (plasma HIV-1 RNA \< 50 c/mL) and have confirmed plasma HIV-1 RNA \>= 400 c/mL at any time during the study. b) Participants who were discontinued before achieving viral suppression (plasma HIV-1 RNA \< 50 c/mL) after Week 8 with last plasma HIV-1 RNA \>=400 c/mL.

Time frame:
Up to Week 96
Reported as:
Count of participants · Participants
Number of Participants With Newly-emergent Genotypic Substitutions at Week 96
ParticipantsFTR 400 mg BID/RAL/TDFFTR 800 mg BID/RAL/TDFFTR 600 mg QD/RAL/TDFFTR 1200 mg QD/RAL/TDFATV/r/RAL/TDF
PI substitution31220
RT substitution21221
Integrase RAL substitution22130
SecondaryMaximum Change From Baseline in Inhibitory Concentration at 50% (IC50) Fold Change Among Participants With VF at Week 24

Virologic failure is defined clinically as confirmed plasma HIV-1 RNA \>= 50 copies/mL at Week 24 or later or virologic rebound defined as confirmed HIV-1 RNA \>=50 copies/mL at any time after prior confirmed suppression to \<50 copies/mL OR confirmed \>1 log10 copies/mL increase in HIV-1 RNA at any time above nadir level where nadir was \>= 50 copies/mL . The phenotypic resistance to a drug is defined as a fold change (i.e, ratio of the IC50 of the clinical isolate to the IC50 of the reference strain) greater than the cut-off for reduced susceptibility. Maximum change from Baseline in Temsavir IC50 fold change based on all on-treatment values has been presented. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment and those values are absolute values. Change from Baseline was calculated as value at indicated time point minus Baseline value. Only those participants available at the specified time points were analyzed.

Time frame:
Baseline and up to Week 24
Reported as:
Mean · IC50 Fold Change
Maximum Change From Baseline in Inhibitory Concentration at 50% (IC50) Fold Change Among Participants With VF at Week 24
IC50 Fold ChangeFTR 400 mg BID/RAL/TDFFTR 800 mg BID/RAL/TDFFTR 600 mg QD/RAL/TDFFTR 1200 mg QD/RAL/TDF
Maximum Change From Baseline in Inhibitory Concentration at 50% (IC50) Fold Change Among Participants With VF at Week 24-2.350 ± 3.45361014.748 ± 2015.5876101.627 ± 190.484939.030 ± 55.1119
SecondaryChange From Baseline in IC50 Fold Change Among Participants With VF at Week 48

Virologic failure is defined clinically as confirmed plasma HIV-1 RNA \>= 50 copies/mL at Week 24 or later or later or virologic rebound defined as confirmed HIV-1 RNA \>=50 copies/mL at any time after prior confirmed suppression to \<50 copies/mL OR confirmed \>1 log10 copies/mL increase in HIV-1 RNA at any time above nadir level where nadir was \>= 50 copies/mL. The phenotypic resistance to a drug is defined as a fold change (i.e, ratio of the IC50 of the clinical isolate to the IC50 of the reference strain) greater than the cut-off for reduced susceptibility. Maximum change from Baseline in Temsavir IC50 fold change based on all on-treatment values has been presented. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment and those values are absolute values. Change from Baseline was calculated as value at indicated time point minus Baseline value. Only those participants available at the specified time points were analyzed.

Time frame:
Baseline and up to Week 48
Reported as:
Mean · IC50 Fold Change
Change From Baseline in IC50 Fold Change Among Participants With VF at Week 48
IC50 Fold ChangeFTR 400 mg BID/RAL/TDFFTR 800 mg BID/RAL/TDFFTR 600 mg QD/RAL/TDFFTR 1200 mg QD/RAL/TDF
Change From Baseline in IC50 Fold Change Among Participants With VF at Week 48-2.624 ± 3.2819586.776 ± 1521.912681.729 ± 165.4931449.092 ± 647.9828
SecondaryChange From Baseline in IC50 Fold Change Among Participants With VF at Week 96

Virologic failure is defined clinically as confirmed plasma HIV-1 RNA \>= 50 copies/mL at Week 24 or later or virologic rebound defined as confirmed HIV-1 RNA \>=50 copies/mL at any time after prior confirmed suppression to \<50 copies/mL OR confirmed \>1 log10 copies/mL increase in HIV-1 RNA at any time above nadir level where nadir was \>= 50 copies/mL. The phenotypic resistance to a drug is defined as a fold change (i.e, ratio of the IC50 of the clinical isolate to the IC50 of the reference strain) greater than the cut-off for reduced susceptibility. Maximum change from Baseline in Temsavir IC50 fold change based on all on-treatment values has been presented. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment and those values are absolute values. Change from Baseline was calculated as value at indicated time point minus Baseline value. Only those participants available at the specified time points were analyzed.

Time frame:
Baseline and up to Week 96
Reported as:
Mean · IC50 Fold Change
Change From Baseline in IC50 Fold Change Among Participants With VF at Week 96
IC50 Fold ChangeFTR 400 mg BID/RAL/TDFFTR 800 mg BID/RAL/TDFFTR 600 mg QD/RAL/TDFFTR 1200 mg QD/RAL/TDF
Change From Baseline in IC50 Fold Change Among Participants With VF at Week 9625.480 ± 68.9030419.901 ± 1092.592946.351 ± 157.9219777.818 ± 1550.8887

Adverse events

Collected over Serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from start of study treatment (Day 1) until 2117 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
FTR/RAL/TDF Total3/200 (1.5%)35/200 (17.5%)163/200 (81.5%)
ATV/r/RAL/TDF0/51 (0%)8/51 (15.7%)46/51 (90.2%)
Most frequent serious events
Showing 10 of 45
Most frequent serious events
EventFTR/RAL/TDF TotalATV/r/RAL/TDF
InfluenzaInfections and infestations0/2001/51
PneumoniaInfections and infestations0/2001/51
Pyelonephritis acuteInfections and infestations0/2001/51
OverdoseInjury, poisoning and procedural complications3/2001/51
Ankle fractureInjury, poisoning and procedural complications0/2001/51
DiarrhoeaGastrointestinal disorders1/2001/51
Abdominal pain upperGastrointestinal disorders0/2001/51
MigraineNervous system disorders0/2001/51
CholelithiasisHepatobiliary disorders0/2001/51
Bone tuberculosisInfections and infestations2/2000/51
Most frequent other events
Showing 10 of 35
Most frequent other events
EventFTR/RAL/TDF TotalATV/r/RAL/TDF
HyperbilirubinaemiaHepatobiliary disorders0/20011/51
DiarrhoeaGastrointestinal disorders37/20010/51
HeadacheNervous system disorders38/2006/51
NasopharyngitisInfections and infestations32/2005/51
JaundiceHepatobiliary disorders0/2008/51
Urinary tract infectionInfections and infestations28/2006/51
Upper respiratory tract infectionInfections and infestations27/2007/51
InfluenzaInfections and infestations22/2007/51
Ocular icterusHepatobiliary disorders1/2007/51
GastroenteritisInfections and infestations11/2006/51

Baseline characteristics

Age, Continuous
Age, Continuous(Years)FTR 400 mg BID/RAL/TDFFTR 800 mg BID/RAL/TDFFTR 600 mg QD/RAL/TDFFTR 1200 mg QD/RAL/TDFATV/r/RAL/TDFTotal
Mean38.1 ± 8.1738.4 ± 9.4940.1 ± 9.4539.2 ± 11.4139.7 ± 10.6339.1 ± 9.84
Sex: Female, Male
Sex: Female, Male(Participants)FTR 400 mg BID/RAL/TDFFTR 800 mg BID/RAL/TDFFTR 600 mg QD/RAL/TDFFTR 1200 mg QD/RAL/TDFATV/r/RAL/TDFTotal
Female1921221622100
Male3128293429151
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)FTR 400 mg BID/RAL/TDFFTR 800 mg BID/RAL/TDFFTR 600 mg QD/RAL/TDFFTR 1200 mg QD/RAL/TDFATV/r/RAL/TDFTotal
African American/African Heritage141516181376
American Indian Or Alaska Native001113
Asian020002
White201917162395
Other/Mixed161317151475
08

Study locations

56 sites
  • GSK Investigational Site
    San Francisco, California 94102, United States
  • GSK Investigational Site
    San Francisco, California 94115, United States
  • GSK Investigational Site
    Washington, District of Columbia 20009, United States
  • GSK Investigational Site
    Coral Gables, Florida 33134, United States
  • GSK Investigational Site
    Orlando, Florida 32803, United States
  • GSK Investigational Site
    Atlanta, Georgia 30312, United States
  • GSK Investigational Site
    New York, New York 10008, United States
  • GSK Investigational Site
    Durham, North Carolina 27710, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45267-0405, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19104, United States
  • GSK Investigational Site
    Austin, Texas 78705, United States
  • GSK Investigational Site
    Dallas, Texas 75246, United States
  • GSK Investigational Site
    Longview, Texas 75605, United States
  • GSK Investigational Site
    Ciudad de Buenos Aires, Buenos Aires C1202ABB, Argentina
  • GSK Investigational Site
    Rosario, Santa Fe 2000, Argentina
  • GSK Investigational Site
    Buenos Aires, C1141ACG, Argentina
  • GSK Investigational Site
    Buenos Aires, C1426EGR, Argentina
  • GSK Investigational Site
    Córdoba, X5000JJS, Argentina
  • GSK Investigational Site
    Rosario, S2000CXP, Argentina
  • GSK Investigational Site
    Bogota, Colombia
  • GSK Investigational Site
    Bogoto, Colombia
  • GSK Investigational Site
    Bogotá, Colombia
  • GSK Investigational Site
    Bonn, Nordrhein-Westfalen 53127, Germany
  • GSK Investigational Site
    Berlin, 12157, Germany
  • GSK Investigational Site
    Hamburg, 20099, Germany
  • GSK Investigational Site
    München, 80336, Germany
  • GSK Investigational Site
    Guadalajara, Jalisco 44280, Mexico
  • GSK Investigational Site
    Zapopan, Jalisco 45170, Mexico
  • GSK Investigational Site
    San Luis Potosi, San Luis Potosí 78240, Mexico
  • GSK Investigational Site
    Aguascalientes, 20230, Mexico
  • GSK Investigational Site
    DF, 14000, Mexico
  • GSK Investigational Site
    Distrito Federal, 03720, Mexico
  • GSK Investigational Site
    Mexico City, 3100, Mexico
  • GSK Investigational Site
    Iquitos, Loreto Iqui 01, Peru
  • GSK Investigational Site
    Lima, 13, Peru
  • GSK Investigational Site
    Lima, 1, Peru
  • GSK Investigational Site
    Lima, 32, Peru
  • GSK Investigational Site
    Lima, 4, Peru
  • GSK Investigational Site
    Lima, Lima 11, Peru
  • GSK Investigational Site
    Lima, Lima 31, Peru
  • GSK Investigational Site
    Bucharest, 021105, Romania
  • GSK Investigational Site
    Constanta, 900709, Romania
  • GSK Investigational Site
    Craiova, Romania
  • GSK Investigational Site
    Iasi, 700116, Romania
  • GSK Investigational Site
    Saint-Petersburg, 191167, Russian Federation
  • GSK Investigational Site
    Smolensk, 214006, Russian Federation
  • GSK Investigational Site
    St. Petersburg, 190103, Russian Federation
  • GSK Investigational Site
    St. Petersburg, 196645, Russian Federation
  • GSK Investigational Site
    Dundee, KwaZulu- Natal 3000, South Africa
  • GSK Investigational Site
    Durban, 4001, South Africa
  • GSK Investigational Site
    Johannesburg, 2010, South Africa
  • GSK Investigational Site
    Observatory, Cape Town, 7925, South Africa
  • GSK Investigational Site
    Badalona, 08916, Spain
  • GSK Investigational Site
    Barcelona, 08036, Spain
  • GSK Investigational Site
    Córdoba, 14004, Spain
  • GSK Investigational Site
    Madrid, 28046, Spain
09

References and documents

Publications

  • Thompson M, Lalezari JP, Kaplan R, Pinedo Y, Pena OAS, Cahn P, Stock DA, Joshi SR, Hanna GJ, Lataillade M; AI438011 study team. Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in antiretroviral-experienced subjects: week 48 analysis of AI438011, a Phase IIb, randomized controlled trial. Antivir Ther. 2017;22(3):215-223. doi: 10.3851/IMP3112. Epub 2016 Dec 6. PubMed 27922453 ↗
  • Landry I, Zhu L, Abu Tarif M, Hruska M, Sadler BM, Pitsiu M, Joshi S, Hanna GJ, Lataillade M, Boulton DW, Bertz RJ. Model-Based Phase 3 Dose Selection for HIV-1 Attachment Inhibitor Prodrug BMS-663068 in HIV-1-Infected Patients: Population Pharmacokinetics/Pharmacodynamics of the Active Moiety, BMS-626529. Antimicrob Agents Chemother. 2016 Apr 22;60(5):2782-9. doi: 10.1128/AAC.02503-15. Print 2016 May. PubMed 26902761 ↗
  • Lalezari JP, Latiff GH, Brinson C, Echevarria J, Trevino-Perez S, Bogner JR, Thompson M, Fourie J, Sussmann Pena OA, Mendo Urbina FC, Martins M, Diaconescu IG, Stock DA, Joshi SR, Hanna GJ, Lataillade M; AI438011 study team. Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial. Lancet HIV. 2015 Oct;2(10):e427-37. doi: 10.1016/S2352-3018(15)00177-0. Epub 2015 Sep 1. PubMed 26423650 ↗
  • Zhou N, Nowicka-Sans B, McAuliffe B, Ray N, Eggers B, Fang H, Fan L, Healy M, Langley DR, Hwang C, Lataillade M, Hanna GJ, Krystal M. Genotypic correlates of susceptibility to HIV-1 attachment inhibitor BMS-626529, the active agent of the prodrug BMS-663068. J Antimicrob Chemother. 2014 Mar;69(3):573-81. doi: 10.1093/jac/dkt412. Epub 2013 Oct 14. PubMed 24128669 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2011 to primary completion in Feb 2013, 18 months.

Results were first posted in Nov 2018, 5 years 8 months after primary completion.

Of 42 industry-sponsored phase 2 interventional studies under Infections, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 18 months is above that.

Counting every sponsor, half of 77 studies reached it within 16 months; a quarter within 10 and three quarters within 47.

Infections covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2011
First posted
Jun 29, 2011
StartActual
Jul 26, 2011
Primary completionActual
Feb 18, 2013
CompletionActual
May 12, 2017
Results first posted
Nov 14, 2018
Last update
Nov 14, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 14, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01384734
Lead sponsor
ViiV Healthcare
Responsible party
Sponsor
First posted
Jun 29, 2011
Start date
Jul 26, 2011
Primary completion
Feb 18, 2013
Completion
May 12, 2017
Results posted
Nov 14, 2018
Last update
Nov 14, 2018

Study contacts

GSK Clinical Trials
study director · ViiV Healthcare

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fostemsavir

Start the discussion